Impact of Sex in the Efficacy of Perioperative Desensitization Procedures in Heart Transplantation: A Retrospective Cohort Study.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 19 02 2021
accepted: 18 06 2021
entrez: 26 7 2021
pubmed: 27 7 2021
medline: 1 10 2021
Statut: epublish

Résumé

Sensitized patients, i.e. recipients with preformed donor-specific HLA antibodies (pfDSA), are at high-risk of developing antibody-mediated rejections (AMR) and dying after heart transplantation (HTx). Perioperative desensitization procedures are associated with better outcomes but can cause sensitization, which may influence their efficacy. In sensitized patients (pfDSA>1000 mean immunofluorescence (MFI) units), we assessed the effect of perioperative desensitization by comparing treated patients to a historical control cohort. Multivariable survival analyses were performed on the time to main outcome, a composite of death and biopsy-proven AMR with 5-year follow-up. The study included 68 patients: 31 control and 37 treated patients. There was no difference in preoperative variables between the two groups, including cumulative pfDSA [4026 (1788;8725) Perioperative desensitization was associated with fewer AMR and deaths after HTx, and efficacy was more pronounced in men than women.

Sections du résumé

Background
Sensitized patients, i.e. recipients with preformed donor-specific HLA antibodies (pfDSA), are at high-risk of developing antibody-mediated rejections (AMR) and dying after heart transplantation (HTx). Perioperative desensitization procedures are associated with better outcomes but can cause sensitization, which may influence their efficacy.
Methods
In sensitized patients (pfDSA>1000 mean immunofluorescence (MFI) units), we assessed the effect of perioperative desensitization by comparing treated patients to a historical control cohort. Multivariable survival analyses were performed on the time to main outcome, a composite of death and biopsy-proven AMR with 5-year follow-up.
Results
The study included 68 patients: 31 control and 37 treated patients. There was no difference in preoperative variables between the two groups, including cumulative pfDSA [4026 (1788;8725)
Conclusion
Perioperative desensitization was associated with fewer AMR and deaths after HTx, and efficacy was more pronounced in men than women.

Identifiants

pubmed: 34305891
doi: 10.3389/fimmu.2021.659303
pmc: PMC8292826
doi:

Substances chimiques

Biomarkers 0
HLA Antigens 0
Immunosuppressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

659303

Informations de copyright

Copyright © 2021 Nguyen, Salem, Bories, Coutance, Amour, Bougle, Suberbielle, Kheav, Carmagnat, Rouvier, Kirsch, Varnous, Leprince and Saheb.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Heart Lung Transplant. 2013 Dec;32(12):1147-62
pubmed: 24263017
Transplantation. 2019 Jul;103(7):1439-1449
pubmed: 30376551
J Heart Lung Transplant. 2017 May;36(5):540-545
pubmed: 27916323
Circulation. 2019 Mar 19;139(12):e553-e578
pubmed: 30776902
Am J Transplant. 2020 Oct;20(10):2791-2801
pubmed: 32180354
Clin J Am Soc Nephrol. 2018 Jan 6;13(1):182-192
pubmed: 28446536
Am J Kidney Dis. 2009 Mar;53(3):370-2
pubmed: 19231737
J Heart Lung Transplant. 2003 Jan;22(1):58-69
pubmed: 12531414
Biol Sex Differ. 2016 Jul 28;7:35
pubmed: 27471591
Transplant Proc. 2012 Jan;44(1):222-5
pubmed: 22310619
J Heart Lung Transplant. 2006 Feb;25(2):153-9
pubmed: 16446213
J Am Soc Nephrol. 2010 Aug;21(8):1398-406
pubmed: 20634297
Eur J Heart Fail. 2019 Oct;21(10):1169-1186
pubmed: 31129923
Circulation. 2018 Jan 2;137(1):71-87
pubmed: 29279339
Lancet. 2002 Mar 2;359(9308):741-6
pubmed: 11888584
J Immunol Res. 2017;2017:6804678
pubmed: 28127571
Am J Transplant. 2019 Apr;19(4):1160-1167
pubmed: 30286278
J Heart Lung Transplant. 2011 Mar;30(3):252-69
pubmed: 21300295
Int J Cardiol. 2018 Aug 15;265:71-76
pubmed: 29605470
Vaccines (Basel). 2019 Aug 06;7(3):
pubmed: 31390822

Auteurs

Lee S Nguyen (LS)

Sorbonne Université, Department of Cardiothoracic Surgery, AP.HP.6 Pitie-Salpetriere, Paris, France.
CMC Ambroise Paré, Research and Innovation, RICAP, Neuilly-sur-Seine, France.
Sorbonne Université, Clinical Investigations Center, AP.HP.6, INSERM, Paris, France.

Joe-Elie Salem (JE)

Sorbonne Université, Clinical Investigations Center, AP.HP.6, INSERM, Paris, France.

Marie-Cécile Bories (MC)

Sorbonne Université, Department of Cardiothoracic Surgery, AP.HP.6 Pitie-Salpetriere, Paris, France.

Guillaume Coutance (G)

Sorbonne Université, Department of Cardiothoracic Surgery, AP.HP.6 Pitie-Salpetriere, Paris, France.

Julien Amour (J)

Jacques Cartier Private Hospital, Department of Cardiothoracic Surgery, Massy, France.

Adrien Bougle (A)

Sorbonne Université, Department of Anesthesiology, AP.HP.6 Pitie-Salpetriere, Paris, France.

Caroline Suberbielle (C)

Saint-Louis Hospital, Immunology Department, Paris, France.

Vissal-David Kheav (VD)

Saint-Louis Hospital, Immunology Department, Paris, France.

Maryvonnick Carmagnat (M)

Saint-Louis Hospital, Immunology Department, Paris, France.

Philippe Rouvier (P)

Sorbonne Université, Department of Anatomopathology, AP.HP.6 Pitie-Salpetriere, Paris, France.

Matthias Kirsch (M)

Department of Cardiovascular Surgery, University Hospital, Lausanne, Switzerland.

Shaida Varnous (S)

Sorbonne Université, Department of Cardiothoracic Surgery, AP.HP.6 Pitie-Salpetriere, Paris, France.

Pascal Leprince (P)

Sorbonne Université, Department of Cardiothoracic Surgery, AP.HP.6 Pitie-Salpetriere, Paris, France.

Samir Saheb (S)

Sorbonne Université, service d'hémobiologie, AP.HP.6 Pitie-Salpetriere, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH